Key result
PTRA plus BMT reduced refractory hypertension vs BMT alone in ARAS, without reducing stroke, renal/cardiac events, or mortality.
Meta-Analysis (n=2,309)
Yes
Answers are grounded in this paper and cite their sources.
OBJECTIVE: For patients with atherosclerotic renal artery stenosis (ARAS), the role of percutaneous transluminal renal angioplasty (PTRA) remains inconclusive. This study aimed to comparatively evaluate the benefits of best medical therapy (BMT) plus PTRA and BMT alone in treating ARAS. METHODS: We performed a systematic review and meta-analysis, and searched for all randomized, controlled trials that reported patients with ARAS. The effectiveness and safety in the BMT plus PTRA and BMT alone groups were estimated, taking into account hypertension, stroke, renal events, cardiac events, and mortality. RESULTS: Nine randomized, controlled trials involving 2309 patients were included. In the BMT plus PTRA group, the incidence of refractory hypertension was significantly lower compared with that in the BMT alone group (odds ratio 0.09; 95% confidence interval 0.01, 0.70). However, there were no significant differences in the rates of stroke, renal events, cardiac events, cardiac mortality, and all-cause mortality between the two groups. CONCLUSIONS: PTRA plus BMT improves blood pressure in patients with ARAS, but there is insufficient evidence for this therapy in improving stroke, renal events, cardiac events, and cardiac and all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) conducted a meta-analysis in Atherosclerotic renal artery stenosis (ARAS) (n=2,309). Percutaneous transluminal renal angioplasty (PTRA) plus best medical therapy (BMT) vs. Best medical therapy (BMT) alone was evaluated on Refractory hypertension (OR 0.09, 95% CI 0.01-0.70). PTRA plus BMT reduced refractory hypertension vs BMT alone in ARAS, without reducing stroke, renal/cardiac events, or mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: